Sign In
Buy SYRE
$98.33
-3.17 (-3.12%)
At Close: Jul 31, 2026
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spyre Therapeutics, Inc. (“Spy
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
07:23pm, Tuesday, 03'rd Dec 2024
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised
Spyre Therapeutics Announces Grants of Inducement Awards
05:03pm, Monday, 02'nd Dec 2024
WALTHAM, Mass. , Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering,
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
08:00am, Monday, 02'nd Dec 2024
Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect
10:00am, Sunday, 01'st Dec 2024
NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASD
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
12:00pm, Wednesday, 27'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors a
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
07:15pm, Tuesday, 26'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are ad
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect
10:00am, Tuesday, 26'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
08:05pm, Monday, 25'th Nov 2024
NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are a
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
05:11pm, Monday, 25'th Nov 2024
WALTHAM, Mass. , Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combin
Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect
10:00am, Monday, 25'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
NEW YORK, NY / ACCESSWIRE / November 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NAS
